Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas

被引:36
|
作者
Richards, ML
Gauger, P
Thompson, NW
Giordano, TJ
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA
[2] Univ Michigan Hosp, Dept Gen Surg, Div Endocrine Surg, Ann Arbor, MI 48109 USA
[3] Univ Michigan Hosp, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1007/s00268-004-7345-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Enterochromaffin-like (ECL) tumors are documented in patients with hypergastrinemia secondary to chronic atrophic gastritis or with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 (ZES-MEN-1). In patients with ECL tumors and atrophic gastritis, normogastrinemia after antrectomy has resulted in resolution, regression, or stabilization of ECL tumors. The natural history of ECL tumors associated with ZES-MEN-1 following normalization of gastrin levels after gastrinoma resection has not been previously reported. The purpose of this study was to determine the course of ECL tumors in patients with ZES-MEN-1 following normalization of serum gastrin levels after gastrinoma resection. Two patients with ZES-MEN-1 had biopsy-proven ECL tumors on endoscopic evaluation. They then underwent surgical exploration that included distal pancreatectomy, enucleation of pancreatic head tumors, duodenotomy with excision of submucosal tumors, and peripancreatic lymphadenectomy. Gastric ECL tumors larger than 1.0 cm were locally excised. Patients underwent long-term follow-up with biochemical and endoscopic surveillance. Normogastrinemia was achieved and sustained following gastrinoma resection in two patients with ZES-MEN-1. Periodic endoscopic surveillance over a 6-year period showed complete resolution of the ECL tumors. The development of ECL tumors associated with ZES-MEN-1 is multifactorial. Studies identified a genetic influence on tumor growth with loss of heterozygosity at the MEN-I gene locus in ECL tumors. The resolution of ECL tumors in ZES-MEN-1 patients who are normogastrinemic indicates that an elevated gastrin level is a primary initiator for development of these tumors. Therefore both genetic defects and hypergastrinemia are causative agents. Normalization of serum gastrin levels is critical for the prevention of aggressive forms of ECL tumors.
引用
收藏
页码:652 / 658
页数:7
相关论文
共 50 条
  • [21] Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome - Discussion
    Wells, SA
    Norton, JA
    Thompson, NW
    Friesen, SR
    ANNALS OF SURGERY, 2001, 234 (04) : 505 - 506
  • [22] MULTIPLE ENDOCRINE NEOPLASIA TYPE-II WITH ZOLLINGER-ELLISON SYNDROME CAUSED BY A SOLITARY PANCREATIC GASTRINOMA
    MATON, PN
    NORTON, JA
    NIEMAN, LK
    DOPPMAN, JL
    JENSEN, RT
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (04): : 535 - 537
  • [23] ZOLLINGER-ELLISON SYNDROME CAN BE THE INITIAL ENDOCRINE MANIFESTATION IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA-TYPE-I
    BENYA, RV
    METZ, DC
    VENZON, DJ
    FISHBEYN, VA
    STRADER, DB
    ORBUCH, M
    JENSEN, RT
    AMERICAN JOURNAL OF MEDICINE, 1994, 97 (05): : 436 - 444
  • [24] GASTRIC ARGYROPHIL CARCINOIDOSIS IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME DUE TO TYPE-1 MULTIPLE ENDOCRINE NEOPLASIA - A NEWLY RECOGNIZED ASSOCIATION
    SOLCIA, E
    CAPELLA, C
    FIOCCA, R
    RINDI, G
    ROSAI, J
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (06) : 503 - 513
  • [25] A case of Zollinger-Ellison syndrome produced by gastrinoma in the duodenum accompanied with multiple endocrine neoplasia type 1
    Yazawa, K
    Kuroda, T
    Watanabe, H
    Shimozawa, N
    Nakata, S
    Fujimori, Y
    Koide, N
    Koike, S
    Kajikawa, S
    Adachi, W
    Amano, J
    HEPATO-GASTROENTEROLOGY, 1999, 46 (25) : 257 - 260
  • [26] A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: Identification of risk factors
    Berna, Marc J.
    Annibale, Bruno
    Marignani, Massimo
    Luong, Tu Vinh
    Corleto, Vito
    Pace, Andrea
    Ito, Tetsuhide
    Liewehr, David
    Venzon, David J.
    Delle Fave, Gianfranco
    Bordi, Cesare
    Jensen, Robert T.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05): : 1582 - 1591
  • [27] THE ZOLLINGER-ELLISON SYNDROME IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE-I (MEN-I)
    VANHEERDEN, JA
    THOMPSON, GB
    PROBLEMS IN GENERAL SURGERY, 1990, 7 (04): : 550 - 563
  • [28] Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1)
    Norton, JA
    Jensen, RT
    SURGICAL ONCOLOGY-OXFORD, 2003, 12 (02): : 145 - 151
  • [29] A Rare Case of Zollinger-Ellison Syndrome and Pancreatic Adenocarcinoma in a Patient with Multiple Endocrine Neoplasia Type 1
    Rosa-Cortes, Pedro
    Micames-Caceres, Carlos
    Laboy-Olivieri, Carlos
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S830 - S830
  • [30] IS SURVEILLANCE WITH GASTRIC ACID MEASUREMENT AND ESOPHAGOGASTRODUODENUOSCOPY (EGD) NECESSARY FOR ALL PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) AND ZOLLINGER-ELLISON SYNDROME (ZES)?
    Schueler, Samuel A.
    Taneja, Sonia L.
    Blau, Jenny E.
    Wank, Stephen
    Kumar, Sheila
    GASTROENTEROLOGY, 2019, 156 (06) : S372 - S372